Priceline.com (NASDAQ:PCLN): Lower than anticipated Q2 bookings guidance could be presented by the company, but Stifel feels that it would create a buying opportunity, as Priceline is set to benefit from any recovery in the European — as well as global — economies. It feels like the guidance will be conservative, and maintains a Buy rating on the shares.
EXFO Inc. (NASDAQ:EXFO): Stifel has brought down its FY2013 estimate for the company from $0.22 to $0.16, based on weaker results from other companies with meaningful exposure to carriers and optical markets, with negative commentary from industry participants. The firm keeps a $7.50 price target and Buy rating on the shares.
Vitamin Shoppe (NYSE:VSI): Susquehanna feels that the company is well positioned for outperformance ahead of its Q1 results, and maintains that the Q4 results were not indicative of the company’s growth prospects, given the expectations for a combination of same store sales strength, margin expansion, and unit growth. It rates the shares at Positive, with a $67 price target.
Don’t Miss: Warren Buffett’s Secret Successor.